In December 2010, the company began sales of the InSpectra TM StO2 Spot Check in countries that recognize the CE Mark and filed for marketing clearance of the product in the United States under the U.S. Food and Drug Administration's Premarket Notification, or 510(k), process. "This handheld device leverages our StO2 measurement technology and enables clinicians to quickly and cost-effectively identify at-risk patients, who can then be continuously monitored with the InSpectra StO2 Tissue Oxygenation Monitor," said Rick Penn, president of the BioMeasurement Division.Penn also said that the clinical and economic evidence supporting wider adoption of StO2 monitoring continues to grow. "Multiple clinical studies demonstrate that patients with low StO2 are at risk of poor outcomes and that a significant percentage of patients in the emergency department and ICU have low StO2 even though their other vital signs are normal," said Penn. Additionally, independent study results were presented at the recent Society of Critical Care Medicine's 40 th Critical Care Congress showing how InSpectra StO2 was used to favorably guide resuscitation of shock patients and improve outcomes in the form of shortened length-of-stays in the ICU and hospital. Based on the compelling results of this initial study, the principal investigator is initiating an independent multi-site outcomes study to demonstrate these results in a larger population of patients.
Hutchinson Technology Reports First Quarter Net Loss
Check Out Our Best Services for Investors
Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Every recommendation goes through 3 layers of intense scrutinyquantitative, fundamental and technical analysisto maximize profit potential and minimize risk.
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.